<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39194204</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects.</ArticleTitle><Pagination><StartPage>e0061324</StartPage><MedlinePgn>e0061324</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00613-24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.00613-24</ELocationID><Abstract><AbstractText>TBAJ-876, a second-generation diarylquinoline with greater antimycobacterial activity and a potentially better safety profile compared with bedaquiline, is under development for the treatment of drug-susceptible and drug-resistant tuberculosis (TB). A phase 1, first-in-human study of TBAJ-876, comprising a single-ascending dose (SAD) part including a food effect cohort, a multiple-ascending dose (MAD) part, and a relative bioavailability part of tablets versus oral suspension, was conducted on 137 healthy adults. A drug-drug interaction study was conducted on 28 healthy adults to evaluate the effects of TBAJ-876 on a cytochrome P450 3A4 substrate (midazolam) and a P-glycoprotein substrate (digoxin). TBAJ-876 was well-tolerated at single doses up to 800 mg and multiple doses up to 200 mg for 14 days. No deaths or serious adverse events occurred. No episodes of clinically significant prolongation of the QTc interval were observed. TBAJ-876 exposures were dose proportional in the SAD and MAD studies. TBAJ-876 exhibited multicompartmental pharmacokinetics (PK) with a long terminal half-life yielding quantifiable concentrations up to the longest follow-up of 10 weeks after a single dose and resulting in accumulation with multiple dosing. In the fed state, TBAJ-876 exposures approximately doubled with the tablet formulation, whereas M3 metabolite exposures decreased by approximately 20%. The relative bioavailability of TBAJ-876 was similar between tablets and the oral suspension at 100-mg doses. With co-administration of TBAJ-876, the AUC<sub>0-inf</sub> of midazolam was unchanged and the C<sub>max</sub> was reduced by 14%; the AUC<sub>0-last</sub> of digoxin was increased by 51%, and the C<sub>max</sub> was increased by 18%. These results support further investigation of TBAJ-876 for the treatment of tuberculosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0001-7383-2495</Identifier><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappas</LastName><ForeName>Fran</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedelman</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickman</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaw-Tsai</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sarah Jaw-Tsai Consulting Services, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olugbosi</LastName><ForeName>Morounfolu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruinenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vast Therapeutics, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beumont</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Alliance for TB Drug Development, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Bill and Melinda Gates Foundation (GF)</Agency><Country /></Grant><Grant><Agency>Department of Foreign Affairs and Trade, Australian Government (DFAT)</Agency><Country /></Grant><Grant><Agency>Irish Aid</Agency><Country /></Grant><Grant><Agency>United States Agency for International Development (USAID)</Agency><Country /></Grant><Grant><Agency>Foreign, Commonwealth and Development Office (FCDO)</Agency><Country /></Grant><Grant><Agency>Bundesministerium für Bildung und Forschung (BMBF)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064687">Diarylquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064687" MajorTopicYN="Y">Diarylquinolines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="Y">Antitubercular Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TBAJ-876</Keyword><Keyword MajorTopicYN="N">antimicrobial safety</Keyword><Keyword MajorTopicYN="N">diarylquinoline</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">phase 1</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39194204</ArticleId><ArticleId IdType="doi">10.1128/aac.00613-24</ArticleId><ArticleId IdType="pmc">PMC11460996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global tuberculosis report. 2023. World Health Organization; Geneva</Citation></Reference><Reference><Citation>WHO consolidated guidelines on tuberculosis. 2022. Geneva: World Health Organiztion</Citation></Reference><Reference><Citation>Putra ON, Yulistiani Y, Soedarsono S, Subay S. 2023. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: a systematic review. Int J Mycobacteriol 12:1–9. doi:10.4103/ijmy.ijmy_217_22</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmy.ijmy_217_22</ArticleId><ArticleId IdType="pubmed">36926755</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm J, Bateson A, Solanki P, Paleckyte A, Witney AA, Rofael SAD, Fabiane S, Olugbosi M, McHugh TD, Sun E. 2023. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob Public Health 3:e0002283. doi:10.1371/journal.pgph.0002283</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0002283</ArticleId><ArticleId IdType="pmc">PMC10584172</ArticleId><ArticleId IdType="pubmed">37851685</ArticleId></ArticleIdList></Reference><Reference><Citation>Satapathy P, Itumalla R, Neyazi A, Nabizai Taraki AM, Khatib MN, Gaidhane S, Zahiruddin QS, Rustagi S, Neyazi M. 2024. Emerging bedaquiline resistance: a threat to the global fight against drug-resistant tuberculosis. J Biosaf Biosec 6:13–15. doi:10.1016/j.jobb.2024.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jobb.2024.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Black T, Upton A, Fotouhi N, Beumont M, Sun E, Nuermberger E, Converse P, Almeida D, Komm O, Franzblau S, Kurepina N, Kreiswirth B. 2023. Antimycobacterial activity of a novel diarylquinoline (TBAJ-876) against diverse drug-susceptible and drug-resistant clinical isolates of M. tuberculosis. Int J Tuberc Lung Dis 27:A13–298.</Citation></Reference><Reference><Citation>Black T, Fotouhi N, Olugbosi M, Beumont M, Sun E, Converse P, Tasneen R, Tyagi S, Almeida D, Komm O, Li S-Y, Nuermberger E. 2023. Enhanced sterilizing potential of regimens containing a novel diarylquinoline (TBAJ-876) in a preclinical mouse model of TB. Int J Tuberc Lung Dis 27:A13–299.</Citation></Reference><Reference><Citation>Almeida D, Converse PJ, Li S-Y, Upton AM, Fotouhi N, Nuermberger EL. 2021. Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrob Agents Chemother 65:e0141221. doi:10.1128/AAC.01412-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01412-21</ArticleId><ArticleId IdType="pmc">PMC8597756</ArticleId><ArticleId IdType="pubmed">34570644</ArticleId></ArticleIdList></Reference><Reference><Citation>van Heeswijk RPG, Dannemann B, Hoetelmans RMW. 2014. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 69:2310–2318. doi:10.1093/jac/dku171</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku171</ArticleId><ArticleId IdType="pubmed">24860154</ArticleId></ArticleIdList></Reference><Reference><Citation>
Janssen therapeutics, division of Janssen products, LP. SIRTURO
(bedaquiline) tablets [package insert]. 2024.
Available from: https://rsc.niaid.nih.gov/clinical-research-sites/bedaquiline-sirturo-package-insert. Retrieved
 Jul 2024.</Citation></Reference><Reference><Citation>Gabrielsson J, Weiner D. 1997. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 2nd Edition, p 145. Kristianstads Boktryckeri AB, Sweden.</Citation></Reference><Reference><Citation>
FDA Center for Drug Evaluation
and Research . 2012.
Clinical pharmacology and biopharmaceutics
review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000ClinPharmR.pdf.</Citation></Reference><Reference><Citation>Smith BP, Vandenh Ende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. 2000. Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278–1283. doi:10.1023/a:1026451721686</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1026451721686</ArticleId><ArticleId IdType="pubmed">11145235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>